


1645



1299 PENNSYLVANIA AVE., NW  
WASHINGTON, DC 20004-2402  
PHONE 202.383.0800  
FAX 202.383.6610  
A LIMITED LIABILITY PARTNERSHIP

RECEIVED  
MAR 28 2002  
FBI CENTER 1600/2900

March 27, 2002



Commissioner for Patents  
Washington, D.C. 20231

Re: U. S. Patent Appl. No. 09/994,927  
Filed: November 28, 2001  
For: **Bisubstituted Carbocyclic Cyclophilin Binding  
Compounds and Their Use**  
Inventors: HAMILTON *et al.*  
Our Ref: 03166.0029.NPUS02

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Information Disclosure Statement;
2. Form PTO-1449 (8 pages) with 150 attached references; and
3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the filing date of these documents and returned to our courier.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No.08-3038 referencing docket number 03166.0029.NPUS02. If extensions of time under 37 C.F.R. § 1.136 other than those otherwise provided for herewith are required to prevent abandonment of the present patent application, then such extensions of time are hereby petitioned. A duplicate copy of this letter is enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael J. Bell".

Michael J. Bell (Reg.No. 39,604)  
Michael J. Stimson (Reg. No. 45,429)

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
HAMILTON, Gregory S., *et al.*

Appl. No. 09/994,927

Filed: November 28, 2001

For: **Bisubstituted Carbocyclic Cyclophilin  
Binding Compounds and Their Use**



Art Unit: To be assigned

Examiner: To be assigned

Attorney Docket: 03166.0029.NPUS02

#6  
HB  
5/9/02

**Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
- ☐ c. Attached is our Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. § 1.17(i), and

- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. \_\_\_\_\_, filed \_\_\_\_\_, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. \_\_\_\_\_, filed \_\_\_\_\_, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 03166.0029.NPUS02.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael J. Bell", with a stylized flourish at the end.

Michael J. Bell (Reg.No. 39,604)

Michael J. Stimson (Reg. No. 45,429)

Date: March 27, 2002

HOWREY SIMON ARNOLD & WHITE, LLP  
Box No. 34  
1299 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004-2402  
(202) 783-0800

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use as many sheets as necessary)

**FORM PTO-1449**

ATTORNEY DOCKET NUMBER

03166.0029.NBVS02

APPLICATION SERIAL NO.

09/994,927

INVENTOR(S)

Hamilton, Gregory S., et al.

FILING DATE

November 28, 2001

GROUP ART UNIT

To be assigned

EXAMINER NAME

To be assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	CITE NO.	U.S. PATENT DOCUMENT NUMBER	DATE OF PUBLICATION MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA1	4,384,999	05/1983	Bollinger et al.			
	AB1	4,681,871	07/1987	Teschemacher et al.			
	AC1	4,703,033	10/1987	Seebach			
	AD1	4,764,503	08/1988	Wenger			
	AE1	4,885,276	12/1989	Witzel			
	AF1	4,914,188	04/1990	Dumont et al.			
	AG1	4,957,903	09/1990	Ranby			
	AH1	5,019,646	05/1991	Furcht et al.			
	AI1	5,100,899	03/1992	Calne			
	AJ1	5,116,816	05/1992	Dreyfuss et al.			
	AK1	5,122,511	06/1992	Dreyfuss et al.			
	AL1	5,134,121	07/1992	Mobley et al.			
	AM1	5,284,826	02/1994	Eberle et al.			
	AN1	5,321,009	06/1994	Baeder et al.			
	AO1	5,330,993	07/1994	Armistead et al.			
	AP1	5,449,612	09/1995	Lepargneur et al.			
	AQ1	5,462,927	10/1995	Mureau et al.			
	AR1	5,464,820	11/1995	Burton et al.			
	AS1	5,478,810	12/1995	Stuber et al.			
	AT1	5,545,719	08/1996	Shashoua			
	AU1	5,614,547	03/1997	Hamilton et al.			
	AV1	5,696,135	12/1997	Steiner et al.			
	AW1	5,721,256	02/1998	Hamilton et al.			
	AX1	5,786,378	07/1998	Hamilton et al.			
	AY1	5,795,908	08/1998	Hamilton et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	CITE NO.	FOREIGN PATENT DOCUMENT NUMBER	DATE OF PUBLICATION MM-DD-YYYY	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AAA1	0 053 029	06/1982	EP				
	AAB1	WO 88/06451	09/1988	PCT				
	AAC1	WO 92/04370	03/1992	PCT				
	AAD1	WO 92/19254	11/1992	PCT				
	AAE1	WO 96/40633	12/1996	PCT				

TECH CENTER 1600/2900

MAR 2 8 2002

RECEIVED

RECEIVED  
MAR 2 8 2002  
TECH CENTER 1600/2900

**LIST OF REFERENCES CITED BY APPLICANT**

(Use as many sheets as necessary)

**FORM PTO-1449**

ATTORNEY DOCKET NUMBER

03166.0029.NPUS02

APPLICATION SERIAL NO.

09/994,927

INVENTORS

HAMILTON, Gregory S., et al.

FILING DATE


November 28, 2001

GROUP ART UNIT

To be assigned

EXAMINER NAME

To be assigned


**RECEIVED**  
MAR 28 2002  
TECHNICAL CENTER 1600/2000

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	CITE NO.	U.S. PATENT DOCUMENT NUMBER	DATE OF PUBLICATION MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA2	5,798,355	08/1998	Steiner et al.			
	AB2	5,801,187	09/1998	Li et al.			
	AC2	5,801,197	09/1998	Steiner et al.			
	AD2	5,843,960	12/1998	Steiner et al.			
	AE2	5,846,979	12/1998	Hamilton et al.			
	AF2	5,846,981	12/1998	Steiner et al.			
	AG2	5,859,031	01/1999	Hamilton et al.			
	AH2	5,874,449	02/1999	Hamilton et al.			
	AI2	5,898,029	04/1999	Lyons et al.			
	AJ2	6,080,753	06/2000	Lyons et al.			
	AK2	08/761,902					12/09/1996
	AL2	09/321,762					05/28/1999
	AM2	09/656,898					09/07/2000
	AN2	09/860,756					05/21/2001
	AO2	09/947,700					09/07/2001
	AP2	60/291,965					05/21/2001
	AQ2	60/291,966					05/21/2001
	AR2						
	AS2						
	AT2						
	AU2						
	AV2						
	AW2						
	AX2						
	AY2						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	CITE NO.	FOREIGN PATENT DOCUMENT NUMBER	DATE OF PUBLICATION MM-DD-YYYY	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AAA2	WO 97/18828	05/1997	PCT				
	AAB2	WO 97/36869	10/1997	PCT				
	AAC2	WO 98/25950	06/1998	PCT				
	AAD2	WO 01/17953	03/2001	PCT				
	AAE2							

RECEIVED

TECH CENTER 1600/2900

MAR 28 2002

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use as many sheets as necessary)		ATTORNEY DOCKET NUMBER <b>03166.0029.NPUS02</b>	APPLICATION SERIAL NO. <b>09/994,927</b>
<b>FORM PTO-1449</b>		INVENTORS <b>HAMILTON, Gregory S., et al.</b>	
		FILING DATE <b>November 28, 2001</b>	GROUP ART UNIT <b>To be assigned</b>
		EXAMINER NAME <b>To be assigned</b>	
<b>OTHER PRIOR ART OR NON PATENT LITERATURE DOCUMENTS</b>			
EXAMINER INITIALS*	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	AA3	BAETGE, E. Edward, et al., "Neurite Outgrowth in PC12 Cells Deficient in GAP-43," <i>Neuron</i> , Vol. 6, 21-30, January 1991	
	AB3	BARINAGA, M., "Neurotrophic Factors Enter The Clinic," <i>Science</i> 264:772-774.	
	AC3	BASI, Guriqbal S., et al., "Primary Structure and Transcriptional Regulation of GAP-43, a Protein Associated with Nerve Growth," <i>Cell</i> , Vol. 49, 785-791, June 19, 1987	
	AD3	BECK, Klaus D., et al., "Mesencephalic Dopaminergic Neurons Protected by GDNF from Axotomy-Induced Degeneration in the Adult Brain," <i>Nature</i> , 373 (1995) 339-41.	
	AE3	BENOWITZ, Larry I., et al., "A Membrane Phosphoprotein Associated with Neural Development, Axonal Regeneration, Phospholipid Metabolism, and Synaptic Plasticity," <i>TINS</i> , Vol. 10, No. 12, 1987	
	AF3	BIERER, Barbara E., "Two Distinct Signal Transmission Pathways in T Lymphocytes are Inhibited by Complexes Formed Between an Immunophilin and Either FK506 or Rapamycin," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 9231-9235, December 1990	
	AG3	BISBY, M.A., "Dependence of GAP43 (B50, F1) Transport on Axonal Regeneration in Rat Dorsal Root Ganglion Neurons," <i>Brain Research</i> , 458 (1988) 157-161	
	AH3	BIXBY, John L., "Protein Kinase C Is Involved in Laminin Stimulation of Neurite Outgrowth," <i>Neuron</i> 3(3):287-97 (1989)	
	AI3	BREDET, David S., Nitric Oxide Synthase Regulatory Sites," <i>J. Biol. Chem.</i> 267(16) 10976-81 (1992)	
	AJ3	CALVO, Victor, et al., "Interleukin 2 Stimulation of p70 S6 Kinase Activity is Inhibited by the Immunosuppressant Rapamycin," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 7571-7575, August 1992	
	AK3	CHONG, M.S., et al., "GAP-43 mRNA in Rat Spinal Cord and Dorsal Root Ganglia Neurons: Development Changes and Re-expression Following Peripheral Nerve Injury," <i>European Journal of Neuroscience</i> , Vol. 4, pp. 83-895, 1992	
	AL3	CHUNG, Jongkyeong, et al., "Rapamycin-FKBP Specifically Blocks Growth-Dependent Activation of and Signaling by the 70 kd S6 Protein Kinases," <i>Cell</i> , Vol. 69, 1227-1236, June 26, 1992	
	AM3	CONSTANTINI, Lauren C., et al., "A Novel Immunophilin Ligand: Distinct Branching Effects on Dopaminergic Neurons in Culture and Neurotrophic Actions after Oral Administration in an Animal Model of Parkinson's Disease," <i>Neurobiology of Disease</i> , 5 (1998) 97-106	
	AN3	CONSTANTINI, Lauren C., et al., "Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease," <i>European Journal of Neuroscience</i> , 13 (2001) 1085-92.	
	AO3	DAWSON, Ted M., et al., "Immunosuppressant FK506 Enhances Phosphorylation of Nitric Oxide Synthase and Protects Against Glutamate Neurotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 9808-9812, November 1993	
	AP3	DAWSON, Valina L., et al., "Mechanisms of Nitric Oxide - Mediated Neurotoxicity in Primary Brain Cultures," <i>The Journal of Neuroscience</i> , June 1993, 13(6): 2651-2661	
	AQ3	DAWSON, Valina L., et al., "Nitric Oxide Mediates Glutamate Neurotoxicity in Primary Cortical Cultures," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88, pp. 6368-6371, July 1991	
	AR3	DeFRANCO, Anthony L., "Immunosuppressants at Work," <i>Nature</i> , Vol. 352, 754-55, August 29, 1991	

TECH CENTER 1600/2900

MAR 28 2002

RECEIVED



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use as many sheets as necessary)		<b>ATTORNEY DOCKET NUMBER</b> 03166.0029.NPUS02		<b>APPLICATION SERIAL NO.</b> 09/994,927	
<b>FORM PTO-1449</b>		<b>INVENTORS</b> HAMILTON, Gregory S., et al.			
		<b>FILING DATE</b> November 28, 2001		<b>GROUP ART UNIT</b> To be assigned	<b>EXAMINER NAME</b> To be assigned
	AA4	DUMONT, Francis J. et al., "The Immunosuppressive and Toxic Effects of FK-506 are Mechanistically Related: Pharmacology of a Novel Antagonist of FK-506 and Rapamycin," <i>J. Exp. Med.</i> , 1992, 176, 751-760.			
	AB4	DUMONT, Francis J., et al., "Distinct Mechanisms of Suppression of Murine T Cell Activation by the Related Macrolides FK-506 and Rapamycin," <i>The Journal of Immunology</i> , Vol. 144, 251-258, No. 1, January 1, 1990			
	AC4	DUMONT, Francis J., et al., "The Immunosuppressive Macrolides FK-506 and Rapamycin Act as Reciprocal Antagonists in Murine T Cells," <i>The Journal of Immunology</i> , Vol. 144, 1418-1424, No. 4, February 15, 1990			
	AD4	FERRARI, Stefano, et al., "The Immunosuppressant Rapamycin Induces Inactivation of p70 <sup>src</sup> through Dephosphorylation of a Novel Set of Sites," <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 22, pp. 16091-16094, August 5, 1993			
	AE4	FRUMAN, David A., et al., "Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A," <i>Proc. Natl. Acad. Sci. USA</i> 89 (1992) 3686-3690			
	AF4	FUJITA, Ko, et al., "Regulation of the Differentiation of PC12 Pheochromocytoma Cells," <i>Environmental Health Perspectives</i> , Vol. 80, pp. 127-142, 1989			
	AG4	GALAT, Andrzej, et al., "A Rapamycin-Selective 25-kDa Immunophilin," <i>Biochemistry</i> , Vol. 31, No. 8, 1992			
	AH4	GASH, Don M., et al., "Functional recovery in parkinsonian monkeys treated with GDNF," <i>Nature</i> , 380 (1996) 252-255.			
	AI4	GIRARD, Peggy R., et al., "Protein Kinase C and Its 80-Kilodalton Substrate Protein in Neuroblastoma Cell Neurite Outgrowth," <i>Journal of Neurochemistry</i> , Vol. 54, No. 1, 300-306, 1990			
	AJ4	GOLD, Bruce G., et al., "The Immunosuppressant FK506 Increases Functional Recovery and Nerve Regeneration Following Peripheral Nerve Injury," <i>Restorative Neurology and Neuroscience</i> , 6 (1994) 287-296			
	AK4	GRAFSTEIN, Bernice, et al., "Intracellular Transport in Neurons," <i>Physiological Reviews</i> , Vol. 60, No. 4, 1167-1283, October 1980			
	AL4	GREENE, Lloyd A., et al., "Establishment of a Noradrenergic Clonal Line of Rat Adrenal Pheochromocytoma Cells Which Respond to Nerve Growth Factor," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 73, No. 7, pp. 2424-2428, July 1976			
	AM4	HANDSCHUMACHER, Robert E., et al., "Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A," <i>Science</i> , Vol. 226:544-546, November 1984			
	AN4	HASHIMOTO, Seiichi, et al., "Blockage of Nerve Growth Factor Action in PC12h Cells by Staurosporine, a Potent Protein Kinase Inhibitor," <i>Journal of Neurochemistry</i> , Vol. 53, No. 6, 1675-85, 1989			
	AO4	HOFFMAN, Paul N., "Expression of GAP-43, a Rapidly Transported Growth-Associated Protein, and Class II Beta Tubulin, a Slowly Transported Cytoskeletal Protein, Are Coordinated in Regenerating Neurons," <i>The Journal of Neuroscience</i> , March 1989, 9(3) 893-897			
TECH CENTER 1600/2900 MAR 28 2002	AP4	HSIANG, J., et al., "The Effects Of Nerve Growth Factor On The Development Of Septal Cholinergic Neurons In Reaggregate Cell Cultures," <i>Neuroscience</i> , 29 (1989) 209-223.			
	AS4	HSU, Linda, "the Effect of 12-O-Tetradecanoylphorbol-13-Acetate (TPA) on Axonal Elongation and Fasciculation," <i>Anatomy and Embryology</i> , 1989, 179:511-518			
	AS4	ITO, Akira, et al., "The Complete Primary Structure of Calcineurin A, A Calmodulin Binding Protein Homologous with Protein Phosphatases 1 and 2A," <i>Biochemical and Biophysical Research Communications</i> , Vol. 163, No. 3, pp. 1492-1497, 1989			
	AS4	JACKOWSKI, A., "A Neural Injury Repair; Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer," <i>British J. of Neurosurgery</i> , 9 (1995) 303-317.			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		ATTORNEY DOCKET NUMBER 03166.0029.NPUS02	APPLICATION SERIAL NO. 09/994,927
<b>FORM PTO-1449</b>		INVENTORS HAMILTON, Gregory S., et al.	
		FILING DATE November 28, 2001	GROUP ART UNIT To be assigned
		EXAMINER NAME To be assigned	
AA5	JAYARAMAN, Thottala, et al., "FK506 Binding Protein Associated with the Calcium Release Channel (Ryanodine Receptor)", <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 14, pp. 9474-9477, May 15, 1992		
AB5	JIN, Yong Jiu, et al., "The 25-kDa FK506-binding Protein is Localized in the Nucleus and Associates with Casein Kinase II and Nucleolin," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7769-7773, August 1993		
AC5	JIN, Yong-Jiu, et al., "Molecular Cloning of a Membrane-Associated Human FK506- and Rapamycin-binding Protein, FKBP-13," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88, pp. 6677-6681, August 1991		
AD5	JIN, Yong-Jiu, et al., "Molecular Cloning of a 25-kDa High Affinity Rapamycin Binding Protein, FKBP25," <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, pp. 10942-10945, June 5, 1992		
AE5	KITAMURA, Yoshihisa, et al., "Suppressive Effect of FK-506, A Novel Immunosuppressant, Against MPTP-Induced Dopamine Depletion in the Striatum of Young C57BL/6 Mice," <i>Journal of Neuroimmunology</i> , 50 (1994) 221-224		
AF5	KUNO, Takayoshi, et al., "Evidence for a Second Isoform of the Catalytic Subunit of Calmodulin-Dependent Protein Phosphatase (Calcineurin A)," <i>Biochemical and Biophysical Research Communications</i> , Vol. 165, No. 3, pp. 1352-1358, 1989		
AG5	KUNZ, Jeannette, et al., "Target of Rapamycin in Yeast, TOR2, Is an Essential Phosphatidylinositol Kinase Homolog Required for G <sub>1</sub> Progression," <i>Cell</i> , Vol. 73, 585-596, May 7, 1993		
AH5	KUO, Calvin J., "Rapamycin Selectively Inhibits Interleukin-2 Activation of p70 S6 Kinase," <i>Nature</i> , Vol. 358, 70-73, July 2, 1992		
AI5	LEVI, A., et al., "The Mode of Action of Nerve Growth Factor in PC12 Cells," <i>Molecular Neurobiology</i> , Vol. 2, 201-26, 1988		
AJ5	LI, Linxi, et al., "Neurotrophic Agents Prevent Motoneuron Death Following Sciatic Nerve Section in the Neonatal Mouse," <i>Journal of Neurobiology</i> , 25, 7 (1994) 759-66		
AK5	LIEBERMAN, A.R., "The Axon Reaction: A Review of the Principal Features of Perikaryal Responses to Axon Injury," <i>Int. Rev. Neurobiol.</i> 14:49-124 (1971)		
AL5	LIN, Leu-Fen H., et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons," <i>Science</i> , 260 (1993) 1130-32		
AM5	LIU, J., et al., "Inhibition of T Cell Signaling by Immunophilin-Ligand Complexes Correlates with Loss of Calcineurin Phosphatase Activity," <i>Biochemistry</i> 1992, 31, 3896-3901		
AN5	LIU, Jun, et al., "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes," <i>Cell</i> , 66(4); 807-815 (1991)		
AO5	LIU, Yuehueng, et al., "Dephosphorylation of Neuromodulin by Calcineurin," <i>J. Biol. Chem.</i> 264(22) 12800-04 (1989)		
AP5	LYONS, W. Ernest, et al., "Immunosuppressant FK506 Promotes Neurite Outgrowth in Cultures of PC12 Cells and Sensory Ganglia," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 3191-3195, April 1994		
AQ5	MAGAL, Ella, et al., "Effects of ciliary neuronotrophic factor on rat spinal cord neurons in vitro: survival and expression of choline acetyltransferase and low-affinity nerve growth factor receptors," <i>Developmental Brain Research</i> , 63 (1991) 141-150.		
AR5	MAKI, Noboru, et al., "Complementary DNA Encoding the Human T-Cell FK506-binding Protein, A Peptidylprolyl <i>cis-trans</i> Isomerase Distinct from Cyclophilin," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 5440-5443, July 1990		

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use as many sheets as necessary)		ATTORNEY DOCKET NUMBER 03166.0029.NPUS02	APPLICATION SERIAL NO. 09/994,927
<b>FORM PTO-1448</b>		INVENTORS HAMILTON, Gregory S., et al.	
FILING DATE November 28, 2001		GROUP ART UNIT To be assigned	EXAMINER NAME To be assigned
AA6	MATSUOKA, Ichiro, et al., "Cell Type-specific Regulation of Nerve Growth Factor (NGF) Synthesis in Non-Neuronal Cells: Comparison of Schwann Cells with Other Cell Types," <i>The Journal of Neuroscience</i> , October 1991, 11(10): 3165-3177		
AB6	MATTSO, M. P., et al., "Intracellular Messengers in the Generation and Degeneration of Hippocampal Neuroarchitecture," <i>Journal of Neuroscience Research</i> , 21:447-464 (1988)		
AC6	McKEON, Frank, "When Worlds Collide: Immunosuppressants Meet Protein Phosphatases," <i>Cell</i> , Vol. 66, 823-826, September 6, 1991		
AD6	MEHTA, Sujata, et al., "Neurite Outgrowth and Protein Phosphorylation in Chick Embryonic Sensory Ganglia Induced by a Brief Exposure to 12-O-Tetradecanoylphorbol 13-Acetate," <i>Journal of Neurochemistry</i> , Vol. 60, No. 3, 972-81, 1993		
AE6	MEIRI, Karina F., et al., "Monoclonal Antibodies Show That Kinase C. Phosphorylation of GAP-43 during Axonogenesis Is Both Spatially and Temporally Restricted In Vivo," <i>The Journal of Cell Biology</i> , Vol. 112, No. 5, 991-1005, March 1991		
AF6	MORRISON, Richard S., et al., "Inhibition of Protein Kinase C Activity Promotes the Neurotrophic Action of Epidermal and Basic Fibroblast Growth Factors," <i>Brain Research</i> , 473 (1988) 141-146		
AG6	PHELPS, C.H., et al., "Commentary: Potential Use of Nerve Growth Factor to Treat Alzheimer's Disease," <i>Neurobiology of Aging</i> , Vol. 10, pp. 205-207, 1989		
AH6	PR Newswire, Guilford Pharmaceuticals, Inc., "Guilford Pharmaceuticals Announces Completion of NIL-A Phase II Clinical Trial for Parkinson's Disease, First Clinical Evaluation of Neuroimmunophilin Ligands in Parkinson's Disease," Baltimore, July 26, 2001.		
AI6	PRICE, D.J., et al., "Rapamycin-Induced Inhibition of the 70-Kilodalton S6 Protein Kinase," <i>Science</i> , Vol. 257:973-977, August 1992		
AJ6	REINHOLD, David, et al., "The Lack of a Role for Protein Kinase C in Neurite Extension and in the Induction of Ornithine Decarboxylase by Nerve Growth Factor in PC12 Cells," <i>J. Biol. Chem.</i> 264(6): 3538-44 (1989)		
AK6	ROSENTHAL, A., et al., "Primary Structure and mRNA Localization of Protein F1, A Growth-Related Protein Kinase C Substrate Associated with Synaptic Plasticity," <i>The EMBO Journal</i> , Vol. 6, No. 12, pp. 3641-3646, 1987		
AL6	RYBA, M., et al., "Cyclosporine A Prevents Neurological Deterioration of Patients with SAH - A Preliminary Report," <i>Acta Neurochir. (Wien)</i> (1991) 112:25-27		
AM6	SAIKA, Takanori, et al., "Effects of Nerve Crush and Transection on mRNA Levels for Nerve Growth Factor Receptor in the Rat Facial Motoneurons," <i>Molecular Brain Research</i> , 9 (1991) 157-160		
AN6	SCHREIBER, Stuart L., "Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands," <i>Science</i> , Vol. 251, 283-287, January 18, 1991		
AO6	SCHREIBER, Stuart L., et al., "The Mechanism of Action of Cyclosporin A and FK506," <i>Immunology Today</i> , Vol. 13, No. 4, 1992		
AP6	SCHREYER, David J., et al., "Fate of GAP-43 in Ascending Spinal Axons of DRG Neurons After Peripheral Nerve Injury: Delayed Accumulation and Correlation with Regenerative Potential," <i>The Journal of Neuroscience</i> , December 1991, 11(2), 3738-3751		
AQ6	SHARKEY, John, et al., "Immunophilins Mediate the Neuroprotective Effects of FK506 in Focal Cerebral Ischaemia," <i>Nature</i> , Vol. 371, 336-39, September 22, 1994		

RECEIVED  
 MAR 28 2002  
 TECH CENTER 1600/2900

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use as many sheets as necessary)		ATTORNEY DOCKET NUMBER 03166.0029.NPUS02	APPLICATION SERIAL NO. 09/994,927
<b>FORM PTO-1449</b>		INVENTORS HAMILTON, Gregory S., et al.	
		FILING DATE November 28, 2001	GROUP ART UNIT To be assigned
		EXAMINER NAME To be assigned	
AA7	SHIGA, Yusei, et al., "Cyclosporin A Protects Against Ischemia-Reperfusion Injury in the Brain," <i>Brain Research</i> , 595 (1992) 145-148		
AB7	SHRINE, "NGF Receptors Can be Angels of Death," <i>Bioworld Today</i> , 5:1-2.		
AC7	SIMON, Ralph, et al., "Human CNTF and related cytokines: effects on DRG neurone survival," <i>Neuroreport</i> , 7, (1995) 153-157.		
AD7	SKENE, J.H. Pate, "Axonal Growth-Associated Protein," <i>Ann. Rep. Neurosci.</i> 1989, 12:127-56		
AE7	SKENE, J.H. Pate, et al., "Axonally Transported Proteins Associated with Axon Growth in Rabbit Central and Peripheral Nervous Systems," <i>The Journal of Cell Biology</i> , Vol. 89, April 1981, 96-103		
AF7	SKENE, J.H. Pate, et al., "Changes in Axonally Transported Proteins During Axon Regeneration in Toad Retinal Ganglion Cells," <i>The Journal of Cell Biology</i> , Vol. 89, April 1981, 86-95		
AG7	SNIPES, G.J., et al., "Regulation of Specific Neuronal and Non-neuronal Proteins During Development and Following Injury in the Rat Central Nervous Sytem," <i>Progress in Brain Research</i> , Vol. 71, 155-75, F.J. Seil, E. Herbert and B.M. Carlson (Eds.)		
AH7	SNYDER et al., "Immunophilins and the nervous system," <i>Nature Medicine</i> , Vol. 1 No. 1, 32-37, January 1995		
AI7	SOMMERVILLE, T., et al., "Time-Dependent Differences in the Increase in GAP-43 Expression in Dorsal Root Ganglion Cells After Peripheral Axotomy," <i>Neuroscience</i> , Vol. 45, No. 1, pp. 213-220, 1991		
AJ7	STANDAERT, Robert F., et al., "Molecular Cloning and Overexpression of the Human FK-506-binding Protein FKBP," <i>Nature</i> , Vol. 346, 671-674, August 16, 1990		
AK7	STEINER, Joseph P., et al., "High Brain Densities of the Immunophilin FKBP colocalized with calcineurin," <i>Nature</i> , 584-587, Vol. 358, August 13, 1992		
AL7	STEINER, Joseph P., et al., "Neurotrophic Actions of Nonimmunosuppressive Analogues of Immunosuppressive Drugs FK506, Rapamycin and Cyclosporin A," <i>Nature Medicine</i> , Vol. 3, No. 4, 421-28, April 1997		
AM7	STEINER, Joseph P., et al., "Neurotrophic Immunophilin Ligands Stimulate Structural and Functional Recovery in Neurodegenerative Animal Models," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 2019-2024, March 1997		
AN7	STREIT, Wolfgang J., et al., "Response of Endogenous Glial Cells to Motor Neuron Degeneration Induced by Toxic Ricin," <i>The Journal of Comparative Neurology</i> , 268:248-263 (1988)		
AO7	SWANSON, Selene K.H., et al., "Cylosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B," <i>Biochemistry</i> , Vol. 89, pp. 3741-3745, May 1992		
AP7	TAI, Ping-Kaung Ku, et al., "Association of a 59-Kilodalton Immunophilin with the Glucocorticoid Receptor Complex," <i>Science</i> , Vol. 256, 1315-18, May 29, 1992		
AQ7	TANAKA, T. et al., "Human Leukocyte Cathepsin G. Subsite Mapping with 4-Nitroanilides, Chemical Modification, and Effect of Possible Cofactors," <i>Biochem.</i> , 1985, 24, 2040-2047.		
AR7	TEICHNER, Angela, et al., "Treatment with Cyclosporine A Promotes Axonal Regeneration in Rats Submitted to Transverse Section of the Spinal Cord," <i>Journal fur Hirnforschung</i> , 34 (1993)3, 343-349		

RECEIVED  
 MAR 2 8 2002  
 TECH CENTER 1600/2903

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use as many sheets as necessary)		<b>ATTORNEY DOCKET NUMBER</b> 03166.0029.NPUS02		<b>APPLICATION SERIAL NO.</b> 09/994,927	
<b>FORM PTO-1449</b>					
<b>INVENTORS</b> HAMILTON, Gregory S., et al.					
		<b>FILING DATE</b> November 28, 2001		<b>GROUP ART UNIT</b> To be assigned	
				<b>EXAMINER NAME</b> To be assigned	
AA8	TETZLAFF, W., et al., "Axonal Transport and Localization of B-50/GAP-43-like Immunoreactivity in Regenerating Sciatic and Facial Nerves of the Rat," <i>The Journal of Neuroscience</i> , April 1989, 9(4), 1303-1313				
AB8	TETZLAFF, Wolfram, et al., "Response of Facial and Rubrospinal Neurons to Axotomy: Changes in mRNA Expression for Cytoskeletal Proteins and GAP-43," <i>The Journal of Neuroscience</i> , August 1991, 11(8): 2528-2544				
AC8	THOENEN, H., et al., "Physiology of Nerve Growth Factor," <i>Physiological Reviews</i> , Vol. 60, No. 4, 1284-1335, October 1980				
AD8	TIMERMAN, Anthony P., et al., "The Calcium Release Channel of Sarcoplasmic Reticulum is Modulated by FK-506-binding Protein," <i>The Journal of Biological Chemistry</i> , 268 (31): 22992-9 (1993)				
AE8	TINDALL, Richard S.A., "Immunointervention with Cyclosporin A in Autoimmune Neurological Disorders," <i>Journal Autoimmun.</i> 1992 Apr., 5 Suppl. A: 301-13				
AF8	TOMAC, A., et al., "Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo," <i>Nature</i> , 373 (1995) 335-9.				
AG8	TRUPP, Miles, et al., "Peripheral Expression of Biological Activities of GDNF, a New Neurotrophic Factor for Avian and Mammalian Peripheral Neurons," <i>Journal of Cell Biology</i> , 130 (1995) 137-148.				
AH8	TUSZYNSKI, Mark H., et al., "Nerve Growth Factor Infusion in the Primate Brain Reduces Lesion-Induced Cholinergic Neuronal Degeneration," <i>Journal of Neuroscience</i> , 10, 11(1990) 3604-3614.				
AI8	VAN der ZEE, Catharina E.E.M., et al., "Expression of Growth-Associated Protein B-50 (GAP43) in Dorsal Root Ganglia and Sciatic Nerve During Regenerative Sprouting," <i>The Journal of Neuroscience</i> , October 1989, 9(10), 3505-3512				
AJ8	VERGE, V.M.K., et al., "Correlation Between GAP43 and Nerve Growth Factor Receptors in Rat Sensory Neurons," <i>The Journal of Neuroscience</i> , March 1990, 10(3), 926-934				
AK8	WIESE, U.H., et al., "Differential Expression of Growth-Associated Protein (GAP-43) mRNA in Rat Primary Sensory Neurons After Peripheral Nerve Lesion: A Non-Radioactive In Situ Hybridisation Study," <i>Brain Res.</i> 592:141-56 (1992)				
AL8	WILEY, Ronald G., et al., "Suicide Transport: Destruction of Neurons by Retrograde Transport of Ricin, Abrin, and Modeccin," <i>Science</i> , Vol. 216:889-890, May 1982				
AM8	WILLIAMS, Lawrence R., et al., "Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection," <i>Proc. Natl. Acad. Sci.</i> , 83, (1986) 9231-9235.				
AN8	WOOLF, C.J., et al., "The Growth-Associated Protein GAP-43 Appears in Dorsal Root Ganglion Cells and in the Dorsal Horn of the Rat Spinal Cord Following Peripheral Nerve Injury," <i>Neuroscience</i> 34(2): 465-78 (1990)				
AO8	YANKNER, Bruce A., et al., "Transfection of PC12 Cells with the Human GAP-43 Gene: Effects on Neurite Outgrowth and Regeneration," <i>Molecular Brain Research</i> , 7 (1990) 39-44				
AP8	YEM, Anthony W., et al., "The Hsp56 Component of Steroid Receptor Complexes Binds to Immobilized FK506 and Shows Homology to FKBP-12 and FKBP-13," <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 5, pp. 2868-2871, February 15, 1992				
<b>EXAMINER SIGNATURE</b>			<b>DATE CONSIDERED</b>		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

RECEIVED  
MAR 28 2002  
TECH CENTER 1600/2900